Treatment adherence with the easypod™ growth hormone electronic auto-injector and patient acceptance: survey results from 824 children and their parents

Table 2 Characteristics of the evaluable survey population

	Total (N = 824)	Treatment-naïve (n = 601)	Treatment-experienced (n = 223)
Boys, n (%)^a	462 (56.1)	358 (59.6)	104 (46.9)
Age, median (range), years	11 (1-18)	11 (1-18)	11 (2-18)
Indication, n (%)^b
GHD	543 (66.4)	407 (68.1)	136 (61.8)
TS	80 (9.8)	46 (7.7)	34 (15.5)
CRF	14 (1.7)	10 (1.7)	4 (1.8)
SGA	125 (15.3)	98 (16.4)	27 (12.3)
Other	56 (6.8)	37 (6.2)	19 (8.6)
Administration of injections^c
Child	315 (38.7)	224 (37.5)	91 (41.7)
Parent	430 (52.8)	317 (53.1)	113 (51.8)
Other	7 (0.86)	6 (1.01)	1 (0.46)
Child and parent	59 (7.2)	46 (7.7)	13 (6.0)
Parent and other	4 (0.49)	4 (0.67)	0
Number of scheduled injections per week^d
6	234 (29.3)	177 (30.2)	57 (26.9)
7	564 (70.7)	409 (69.8)	155 (73.1)

^aOne child missing from the treatment-experienced group.
^bSix children missing: three each from the treatment-naïve and treatment-experienced groups.
^CNine children missing: four from the treatment-naïve group and five from the treatment-experienced group.
^dTwenty-six children missing: fifteen from the treatment-naïve group and eleven from the treatment-experienced group.
CRF -- chronic renal failure; GHD -- growth hormone deficiency; SGA -- small for gestational age; TS -- Turner syndrome.

ISSN: 1472-6823